➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Mallinckrodt
Baxter
Dow
Merck

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,557,852


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,557,852 protect, and when does it expire?

Patent 8,557,852 protects BEVYXXA and is included in one NDA.

This patent has thirty-two patent family members in twenty countries.

Summary for Patent: 8,557,852
Title:Methods of using crystalline forms of a salt of a factor Xa inhibitor
Abstract: The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa. ##STR00001##
Inventor(s): Grant; Craig (Burwell, GB), Kanter; James P. (San Ramon, CA), Langlands; Graeme (Soham, GB)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/550,291
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,557,852

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ⤷  Free Forever Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial PROPHYLAXIS OF VENOUS THROMBOSIS ⤷  Free Forever Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) ⤷  Free Forever Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial PROPHYLAXIS OF VENOUS THROMBOSIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,557,852

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 056787 ⤷  Free Forever Trial
Argentina 106960 ⤷  Free Forever Trial
Austria 549317 ⤷  Free Forever Trial
Australia 2006311544 ⤷  Free Forever Trial
Brazil PI0618362 ⤷  Free Forever Trial
Canada 2627086 ⤷  Free Forever Trial
China 101304971 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Johnson and Johnson
McKinsey
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.